OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro …
DL White, VA Saunders, P Dang, J Engler… - Blood, 2006 - ashpublications.org
Intrinsic sensitivity of newly diagnosed chronic myeloid leukemia (CML) patients to imatinib (IC50
imatinib ) correlates with molecular response. IC50 imatinib is defined as the in vitro …
imatinib ) correlates with molecular response. IC50 imatinib is defined as the in vitro …
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 …
DL White, VA Saunders, P Dang… - Blood, The Journal …, 2007 - ashpublications.org
Interpatient variability in intracellular uptake and retention (IUR) of imatinib may be due to
variable function of the OCT-1 influx pump. OCT-1 activity was measured in pretherapy blood …
variable function of the OCT-1 influx pump. OCT-1 activity was measured in pretherapy blood …
[PDF][PDF] Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
…, J Engler, A Frede, S Zrim, M Osborn, VA Saunders… - J Clin Oncol, 2010 - academia.edu
Purpose Organic cation transporter-1 (OCT-1) activity (OA), a measure of the OCT-1–mediated
influx of imatinib into CML mononuclear cells (MNCs), is predictive of major molecular …
influx of imatinib into CML mononuclear cells (MNCs), is predictive of major molecular …
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
…, AK Mills, RJ Filshie, CK Arthur, P Dang, VA Saunders… - Leukemia, 2018 - nature.com
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs),
approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and …
approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and …
[HTML][HTML] The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
Asciminib (previously ABL001), which binds the myristate-binding pocket of the Bcr-Abl
kinase domain, is in phase I clinical trials as monotherapy and in combination with imatinib, …
kinase domain, is in phase I clinical trials as monotherapy and in combination with imatinib, …
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Approximately half of patients with chronic myeloid leukemia (CML) in sustained deep
molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment-free …
molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment-free …
[HTML][HTML] Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure …
Background The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1
activity) is an excellent predictor of molecular response and progression-free survival in …
activity) is an excellent predictor of molecular response and progression-free survival in …
[HTML][HTML] BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
…, IO Kommers, JM Goyne, M Nicola, VA Saunders… - …, 2018 - ncbi.nlm.nih.gov
Accurate quantification of minimal residual disease (MRD) during treatment of chronic myeloid
leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR for …
leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR for …
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib
…, TM Leclercq, P Dang, VA Saunders… - Blood …, 2019 - ashpublications.org
In chronic-phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib,
failure to achieve early molecular response (EMR; EMR failure: BCR-ABL1 >10% on the …
failure to achieve early molecular response (EMR; EMR failure: BCR-ABL1 >10% on the …
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
Imatinib and nilotinib interact with ABCB1 and ABCG2. However, whether they are substrates
or inhibitors is a source of conjecture. Here, in vitro, Bcr–Abl kinase inhibition was used to …
or inhibitors is a source of conjecture. Here, in vitro, Bcr–Abl kinase inhibition was used to …